Introduction {#sec1}
============

The increasing morbidity and mortality caused by cancers pose enormous challenges to public health. Albeit widely used for tumor treatment, surgical resection is often plagued by limited visibility of tumor foci, which causes incomplete surgical ablation and tumor recurrence. Conventional dyes lack the specificity to recognize tumor cells. To increase tumor-to-healthy tissue signal contrast, dyes are often conjugated with tumor-targeting entities such as antibody or peptides.^[@ref1]−[@ref3]^ In addition, small-molecule probes are prone to dissipation from tumor tissues over time, limiting their applications in clinical settings. Hence, optical reagents that could accumulate and be retained in tumors over time are of practical use to assist tumor surgery.^[@ref4]−[@ref8]^

Mammalian cells have evolved various sugar-sorting pathways to ferry exogenous monosaccharides or endogenous glycoproteins to cognate subcellular locations.^[@ref9]^ For instance, mannose-6-phosphate receptors (M6P-R) effectively address newly biosynthesized hydrolases with M6P-terminating glycans to lysosomes.^[@ref9]−[@ref11]^ Moreover, cancer cells require more glucose for tumor growth. This attribute enables positron-emission tomography (PET) imaging of cancers by 2-deoxy-2-\[^18^F\] fluoro-[d]{.smallcaps}-glucose (^18^F-FDG). Akin to glucose, sialic acid (Sia) is a family of 9-carbon monosaccharides derived from *N*-acetyl-neuraminic acid, which is typically located at termini of cell-surface glycans.^[@ref12]−[@ref15]^

Cell-surface hypersialylation is a characteristic of many cancers and the hypoxic core of solid tumors.^[@ref16]−[@ref18]^ In addition, sialic acid transporters have been reported to be upregulated in certain cancers. These findings suggest elevated metabolic demand of Sia by tumor cells. Fluorescein isothiocyanate-labeled Sia (^FITC^Sia) has been reported for tumor imaging in mice models.^[@ref19],[@ref20]^ As exogenous Sia is uptaken into acidic lysosomes prior to cell sialylation, the performance of ^FITC^Sia is compromised by quenching of fluorescein fluorescence in acidic media owing to protonation of the phenolic group. Herein, we report the use of rhodamine-X conjugated at C9 of Sia (^ROX^Sia) with pH-independent "always-on" fluorescence for high-performance tumor imaging, intense red fluorescence in lysosomes. Long-term retention of imaging agents inside tumor tissues is beneficial for clinical applications. Imaging studies showed that ^ROX^Sia exhibits pH-independent long-term retention in lysosomes in live cells, high tumor-to-health tissue signals contrast, and long-term fluorescence retention in tumor foci in mice, which are advantageous for potential fluorescence-guided tumor surgery ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Schematic For the Use of ROX-Labeled Sialic Acid For In Vivo Tumor Imaging via Sugar Sorting-Mediated Probe Transportation into Lysosomes\
Keys show chemical structures of ^FITC^Sia with acidity-quenched green fluorescence, ^ROX^Sia and ^ROX-Tz^Sia that contain an entity of rhodamine-X of pH-independent intense red fluroescence.](ao0c02323_0005){#sch1}

Results and Discussion {#sec2}
======================

Cellular Uptake of ROX-Conjugated Sia into Lysosomes in Live Cells {#sec2.1}
------------------------------------------------------------------

Over sialylation of cell-surface glycoconjugates is a hallmark of a number of cancer types and the hypoxic cores of solid tumors,^[@ref16]−[@ref18]^ suggesting the applicability of Sia to target tumor foci in vivo. In line with this, the reported use of ^FITC^Sia to target tumor foci showed that Sia with an appropriate substituent at C-9 could be effectively taken up by tumors from the bloodstream.^[@ref19],[@ref20]^ As ^FITC^Sia is transported into acidic lysosomes in tumor foci and fluorescein fluorescence is significantly decreased in acidic conditions, we were keen to examine the performance of ^ROX^Sia, with an entity of acidity-insensitive highly fluorescent rhodamine at C-9, for in vivo tumor imaging. Hence, we synthesized sialic acid derivatives with C-9-linked rhodamine-X via amide (^ROX^Sia) or triazole (^ROX-Tz^Sia) ([Scheme S1 and Figures S1--S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02323/suppl_file/ao0c02323_si_001.pdf), Supporting Information), which is used as a control probe to explore the impact of a linker structure on tumor uptake.

pH titrations ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02323/suppl_file/ao0c02323_si_001.pdf), Supporting Information) showed that ^ROX^Sia and ^ROX-Tz^Sia exhibited an always-on bright red fluorescence emission peak at 615 nm in the range of pH 4--9 ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02323/suppl_file/ao0c02323_si_001.pdf), Supporting Information). With the validated pH-independent fluorescence, we proceeded to investigate the capability of ^ROX^Sia and ^ROX-Tz^Sia to target lysosomes in live cells. Both probes were incubated in Dulbecco's-modified Eagle's medium (DMEM) with a panel of cell lines including HeLa, MCF-7, CHO, HepG2, H22, and A549 cells. These cells were further stained with LysoTracker Green DND-26 (referred to as LysoTracker Green), a commercial dye specific for acidic lysosomes. Colocalization of ROX fluorescence with LysoTracker Green was identified in all of the cell lines examined ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), suggesting selective uptake of ^ROX^Sia and ^ROX-Tz^Sia into acidic lysosomes from a culture medium by mammalian cells.

![Selective staining of lysosomes with ^ROX^Sia (A) and ^ROX-Tz^Sia (B). HeLa, MCF-7, CHO, HepG2, H22, and A549 cells were, respectively, cultivated with ^ROX^Sia (20 μM) or ^ROX-Tz^Sia (20 μM) for 24 h and then stained with LysoTracker Green (1 μM) for 30 min before confocal fluorescence microscopic analysis. Scale bars, 10 μm.](ao0c02323_0001){#fig1}

To further prove acidity-independent fluorescence, HeLa cells were stained with ^ROX^Sia, ^ROX-Tz^Sia, or LysoTracker Red DND-99 (referred to as LysoTracker Red, a commercial dye specific for acidic lysosomes) in the presence of bafilomycin A1 (Baf-A1). Baf-A1 is a potent inhibitor of V-ATPase and neutralizes lysosomes.^[@ref21]^ Baf-A1 caused loss of LysoTracker Red in cells, suggesting loss of LysoTracker Red from lysosomes. In contrast, intense signals of ^ROX^Sia and ^ROX-Tz^Sia were identified inside Baf-A1-positive cells and Baf-A1-free control cells ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), showing acidity-independent fluorescence and retention of both glycoprobes in lysosomes. Next, to verify long-term probe retention in lysosomes, HeLa cells prestained with ^ROX^Sia, ^ROX-Tz^Sia, or LysoTracker Red were further cultured in fresh DMEM for varied periods of time. Time course analysis on intracellular ROX signals revealed robust red fluorescence of both probes in cells after 24 h incubation, whereas no signals of LysoTracker Red could be observed ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B), showing long-term retention of ^ROX^Sia and ^ROX-Tz^Sia over conventional dyes.

![Acidity-independent fluorescence and long-term retention of ^ROX^Sia and ^ROX-Tz^Sia in lysosomes. (A) HeLa cells prestained with ^ROX^Sia (20 μM), ^ROX-Tz^Sia (20 μM), or LysoTracker Red (1 μM) were further incubated in DMEM spiked with or without Baf-A1 (20 nM) for 24 h prior to confocal fluorescence microscopy analysis. (B) HeLa cells prestained with ^ROX^Sia, ^ROX-Tz^Sia (20 μM), or LysoTracker Red (1 μM) were further incubated in fresh DMEM for 24 h before analysis. Scale bars, 10 μm.](ao0c02323_0002){#fig2}

Fluorescence Imaging of Subcutaneous Tumors in Mice with Rox-Labeled Sia {#sec2.2}
------------------------------------------------------------------------

Shown to be fluorescent in lysosomes, ^ROX^Sia and ^ROX-Tz^Sia were further evaluated for their efficacy to illuminate subcutaneous tumors in mice. Nude mice were subcutaneously inoculated with H22 hepatocellular carcinoma cells in the flank. The mice were maintained for 5--10 days after inoculation to allow development of H22 tumor xenografts. ^ROX^Sia and ^ROX-Tz^Sia were, respectively, injected into the tumor-bearing mice via tail vein. The mice were imaged for whole-body fluorescence at 0--144 h following injection. Intense ROX signals are clearly identified in subcutaneous tumors in mice at 24--144 h post treatment with ^ROX^Sia or ^ROX-Tz^Sia ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a1,b1). The mice were sacrificed. The tumors and representative organs were excised and analyzed for ex vivo fluorescence emission. Consistent with the whole-body imaging results, excellent tumor-to-healthy organ fluorescence contrasts are identified in the tumors treated with both glycoprobes ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a2,a3,b2,b3), validating the capacity of ^ROX^Sia and ^ROX-Tz^Sia to illuminate tumors in vivo. As ^FITC^Sia exhibited 1--2 h retention of tumor-associated fluorescence, the long-term fluorescence retention in tumors conformed the beneficial roles of ROX for lysosome retention.

![Time course on whole-body fluorescence of ^ROX^Sia (A) and ^ROX-Tz^Sia (B) in mice bearing H22 subcutaneous tumors. The mice were injected via tail vein with ^ROX^Sia or ^ROX-Tz^Sia (30 mg/kg) and then monitored for whole-body fluorescence for 30 min--144 h following injection. Circles indicate the location of subcutaneous tumors.](ao0c02323_0003){#fig3}

Imaging of Liver Tumor Foci with ^ROX^Sia {#sec2.3}
-----------------------------------------

Liver cancer, constituted mostly by hepatocellular carcinoma, is one of the most common and lethal malignancies with over 600 000 new cases diagnosed annually and a similar number of deaths. To date, cytoreductive surgery combined with chemotherapy remains the major modality for treatment of liver cancer. Hence, approaches that could assist complete surgical removal of cancer cells will be beneficial for cancer treatment. To ascertain whether ^ROX^Sia could be used to discern tumor foci in livers, rats with chemically induced primary hepatocarcinoma (SD rats were given sterile tap water containing 95 μg/mL of dimethylnitrosamine for 1 month, then sterilized tap water for 1 month, and then again sterile tap water containing 95 μg/mL of dimethylnitrosamine for another 70 days) were intravenously administered with ^ROX^Sia. At 48 h after injection, the liver was excised and examined ex vivo. No fluorescence was observed in the liver free of tumor foci, whereas tumor-bearing liver exhibited intensive ROX fluorescence in tumor foci ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The imaging studies showed the capability of ^ROX^Sia to target tumor foci in the liver.

![Imaging of tumor foci in livers with ^ROX^Sia. SD rats with hepatocarcinoma induced by dimethylnitrosamine were intravenously injected with ^ROX^Sia (30 mg/kg) via the tail vein, sacrificed 48 h post injection. The livers were excised and visualized ex vivo by fluorescence analysis. The bar graph shows the fluorescence intensity of ^ROX^Sia in tumor foci vs. the surrounding liver tissue.](ao0c02323_0004){#fig4}

Cytotoxicity of ^ROX^Sia and ^ROX-Tz^Sia {#sec2.4}
----------------------------------------

To determine probe cytoxicity, HeLa cells were cultured with various concentrations of ^ROX^Sia and ^ROX-Tz^Sia in DMEM for 24 h. The cell viability and cell number were determined by MTT assay. No detrimental effects on cell viability were observed at doses up to 75 μM after 24 h incubation ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02323/suppl_file/ao0c02323_si_001.pdf), Supporting Information), indicating that both probes are of low cell toxicity.

Conclusions {#sec3}
===========

We demonstrate the use of sialic acid monosaccharide derivatives with rhodamine-X labeled at C-9 (^ROX^Sia and ^ROX-Tz^Sia) for effective illumination of a subcutaneous tumor and tumor foci via tumor uptake of systemically administered probes. In contrast to ^FITC^Sia, ^ROX^Sia and ^ROX-Tz^Sia exhibited superior fluorescence stability toward lysosomal acidity. The demonstrated in vivo tumor-targeting properties of ^ROX^Sia and ^ROX-Tz^Sia overtime, including high tumor-to-background signal ratios and long-term tumor-associated ROX fluorescence, support their potential for fluorescence-guided intraoperative tumor detection.

Experimental Section {#sec4}
====================

Materials {#sec4.1}
---------

^Az^Sia and ^ROX^Sia were synthesized according to published procedures.^[@ref22],[@ref23]^ 5-ROX-alkyne was obtained from Bioluminor Bio-technology Co., Ltd. (Xiamen, China). Bafilomycin A1 (Baf-A1) was purchased from Selleck (Texas). LysoTracker Green DND-26 and LysoTracker Red DND-99 were obtained from Thermofisher (Massachusetts). All other chemicals were obtained from Alfa-Aesar (Massachusetts) unless otherwise specified. HeLa, A549, CHO, HepG2, H22, and MCF-7 cells were obtained from American Type Culture Collection (ATCC) (Virginia). Female nude mice (6 and 8 weeks of age, ∼20 g) were purchased from the Experimental Animal Center of Xiamen University (Xiamen, China). Fluorescence imaging studies were performed using an IVIS Lumina II Imaging System (Caliper, Boston). The fluorescence spectra were obtained on SpectraMax M5 (Molecular Devices Corporation, California). Confocal fluorescence microscopic imaging was performed on Leica SP5 (Leica, Wetzlar, Germany) using the following filters: λ~ex~ = 488 nm and λ~em~ = 499--553 nm for LysoTracker Green DND-26, λ~ex~ = 565 nm and λ~em~ = 585--650 nm for LysoTracker Red DND-99 and ROX. The fluorescence of ROX, LysoTracker Red in cells was shown in red in the figures and LysoTracker Green in cells was shown in green. Images of merged fluorescence were processed using Photoshop CS6. Graphs were generated by origin 9.1 software (GraphPad Software, Inc., California).

### pH Titration of ^ROX^Sia and ^ROX-Tz^Sia In Vitro {#sec4.1.1}

^ROX-Tz^Sia or ^ROX^Sia was, respectively, added to sodium phosphate buffer (PBS, 100 mM) buffer containing 30% *N*,*N*-dimethylformamide (DMF) (pH: 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0) to a final concentration of 5 μM. Fluorescence spectra were recorded using λ~ex~ = 595 nm for ROX.

### Staining of Cells with ^ROX^Sia and ^ROX-Tz^Sia {#sec4.1.2}

HeLa, A549, CHO, HepG2, H22, and MCF-7 cells cultivated with LysoTracker Green DND-26 (1 μM) for 30 min and ^ROX-Tz^Sia (20 μM) or ^ROX^Sia (20 μM) for 24 h. Then, the cells were analyzed by confocal fluorescence microscopy.

### Imaging of Subcutaneous Tumors in Mice with ^ROX^Sia and ^ROX-Tz^Sia {#sec4.1.3}

Nude mice were xenografted in the flank by subcutaneous injections of H22 cells (1 × 10^6^). At 5--8 days after the transplantation, ^ROX^Sia (30 mg/kg) or ^ROX-Tz^Sia (30 mg/kg) was, respectively, injected intravenously via the tail vein into tumor-bearing mice. At 30 min to 144 h following injection, the mice were analyzed for whole-body NIR fluorescence.

### In Vivo Distribution of ^ROX^Sia and ^ROX-Tz^Sia in Tumor-Bearing Mice {#sec4.1.4}

At 114 h following injection, the mice were executed according to the regulations, the tumors and organs were separated, and finally in vitro fluorescence analysis was done after washing the residual blood with PBS.

### Rat Orthotopic Liver Cancer Imaging of ^ROX^Sia {#sec4.1.5}

Rat with or without orthotopic liver cancer was intravenously injected with ^ROX^Sia in PBS (30 mg/kg, 100 μL). The liver was dissected after 48 h post injection and then imaged for ex vivo fluorescence emission.

### Cytotoxicity of ^ROX^Sia and ^ROX-Tz^Sia {#sec4.1.6}

HeLa cells were cultured in DMEM containing various levels of ^ROX-Tz^Sia (0--75 μM) or ^ROX^Sia (0--75 μM) for 24 h. Cell viability was determined by MTT assay ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02323/suppl_file/ao0c02323_si_001.pdf), Supporting Information).

### Incapability of 5-ROX to Stain Lysosomes {#sec4.1.7}

HeLa cells were cultivated with 5-ROX (20 μM) for 24 h and LysoTracker Green (1 μM) for 30 min. Then, the cells were analyzed by confocal fluorescence microscopy.

### Effects of Exogenous Sia on Staining Lysosomes with ^ROX^Sia and ^ROX-Tz^Sia {#sec4.1.8}

HeLa cells were incubated with ^ROX^Sia (20 μM) or ^ROX-Tz^Sia (20 μM) for 24 h with or without sialic acid (Sia) (2 mM). Then, the cells were visualized by confocal fluorescence microscopy.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c02323](https://pubs.acs.org/doi/10.1021/acsomega.0c02323?goto=supporting-info).The Supporting Information includes the details of synthesis and characterization of ^ROX-Tz^Sia, pH titration and cytotoxicity of probes, control experiments using 5-ROX without sialic acid modification, and sialic acid blocking ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02323/suppl_file/ao0c02323_si_001.pdf))
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Sia

:   sialic acid

ROX

:   rhodamine-X

^ROX^Sia

:   rhodamine-X-conjugated Sia via amide

^ROX-Tz^Sia

:   rhodamine-X-conjugated Sia via triazole

M6P-R

:   mannose-6-phosphate receptors

PET

:   positron-emission tomography

^18^F-FDG

:   2-deoxy-2-\[^18^F\] fluoro-[d]{.smallcaps}-glucose

^FITC^Sia

:   fluorescein isothiocyanate-labeled Sia

Baf-A1

:   Bafilomycin A1

DMEM

:   Dulbecco's-modified Eagle's medium
